8-KItem 1.01 · Material AgreementItem 2.03 · Financial ObligationItem 3.02 · Unregistered Equity SalesItem 8.01 · Other EventsItem 9.01 · Financial Statements
Moderna prices $2.6 billion of convertible notes due 2032
Filed with the SEC on · Summarized by InvestorsBot
Moderna priced $2.6 billion of 0.00% convertible senior notes due March 1, 2032, up from the initially proposed $2.0 billion, with closing expected September 1, 2026. The notes have an initial conversion price of about $210.58 per share and could convert into 14.25 million shares, or up to 21.01 million in limited circumstances; a capped-call hedge costing approximately $285 million is intended to reduce dilution, with proceeds also available for oncology investment, debt repayment and other corporate purposes.